Key result
Extracellular vesicles may act as pathogenic factors, biomarkers, and therapeutic targets in Type 1 diabetes and its associated vascular complications.
Why the study?
Chronic diabetic vascular complications remain the main cause of life reduction in type 1 diabetes, requiring better understanding of mechanisms, identification of predictive biomarkers, and recognition of novel therapeutic targets.
Extracellular vesicles are emerging as key mediators of cellular crosstalk in Type 1 diabetes, offering potential as novel biomarkers and therapeutic targets for disease progression and associated cardiovascular damage.
Significance: Type 1 diabetes (T1D) is characterized by the autoimmune destruction of the insulin secreting β-cells, with consequent aberrant blood glucose levels. Hyperglycemia is the common denominator for most of the chronic diabetic vascular complications, which represent the main cause of life reduction in T1D patients. For this disease, three interlaced medical needs remain: understanding the underlying mechanisms involved in pancreatic β-cell loss; identifying biomarkers able to predict T1D progression and its related complications; recognizing novel therapeutic targets. Recent Advances: Extracellular vesicles (EVs), released by most cell types, were discovered to contain a plethora of different molecules (including microRNAs) with regulatory properties, which are emerging as mediators of cell-to-cell communication at the paracrine and endocrine level. Recent knowledge suggests that EVs may act as pathogenic factors, and be developed into disease biomarkers and therapeutic targets in the context of several human diseases. Critical Issues: EVs have been recently shown to sustain a dysregulated cellular crosstalk able to exacerbate the autoimmune response in the pancreatic islets of T1D; moreover, EVs were shown to be able to monitor and/or predict the progression of T1D and the insurgence of vasculopathies. Future Directions: More mechanistic studies are needed to investigate whether the dysregulation of EVs in T1D patients is solely reflecting the progression of diabetes and related complications, or EVs also directly participate in the disease process, thus pointing to a potential use of EVs as therapeutic targets/tools in T1D. Antioxid. Redox Signal . 36, 631–651.
No takes yet. Share an insight, caveat, or question.
Garavelli et al. (2021) conducted a review in Type 1 diabetes and associated cardiovascular damage. Extracellular vesicles was evaluated. Extracellular vesicles may act as pathogenic factors, biomarkers, and therapeutic targets in Type 1 diabetes and its associated vascular complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: